Liver stiffness and serum galectin 3 level significantly increases in patients with prediabetes: a fibroscan study.

AIM

Diabetes mellitus (DM) is associated with the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). In our study, we aimed to evaluate the relationship between liver stiffness (LS) and galectin-3 levels in patients diagnosed with prediabetes.

METHODS

A total of 120 participants were included in this prospective and cross-sectional study, comprising 40 patients with prediabetes, 40 patients with type 2 DM and 40 individuals with normal glucose metabolism. Human galectin-3 levels were measured using Enzyme-Linked Immunosorbent Assay (ELISA) with Human Galectin-3 kits. LS measurements were performed using the FibroScan® Mini 430 device (Echosens, France).

RESULTS

In our study, we found that Fib-4 index, LS and galectin-3 levels were increased in patients with prediabetes. Another significant finding was that hemoglobin A1c (HbA1c) and galectin-3 levels were higher in patients with LS value ≥8 kPa and both HbA1c and galectin-3 levels were independently associated with LS.

CONCLUSION

Considering the increased prevalence of MASLD in prediabetes, we recommend early assessment of LS and measurement of galectin-3 levels in these patients.